Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Rivaroxaban 20 mg vs Xarelto 20 mg under fed conditions in healthy Thai volunteers
TCTR20210803002Phase 1Not yet recruiting
- Sponsor
- Bio-innova
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in venous thromboembolism (VTE), Atrial fibrillation (AFib), coronary arteriosclerosis and 1 more (2 arms), sponsored by Bio-innova. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)coronary arteriosclerosisarteriosclerosis obliterans
Beyond the preview
Go deeper on TCTR20210803002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20210803002.